Noile-Immune Biotech Inc. (TYO:4893)
Japan · Delayed Price · Currency is JPY 149.00
-3.00 (-1.97%)
At close: Feb 6, 2026
Noile-Immune Biotech Company Description
Noile-Immune Biotech Inc. researches and develops CAR-T cells for novel cancer immunotherapies.
The company’s product pipeline includes, NIB101, a target antigen for solid tumors; NIB102, an autologous CAR-T cell therapy; NIB103, autologous CAR-T cell therapy for mesothelin (MSLN); NIB104, a PRIME technology against target antigens in solid tumors; ADAP01; AUTL01; and CHUG01.
Noile-Immune Biotech Inc. was incorporated in 2015 and is headquartered in Minato, Japan.
Noile-Immune Biotech Inc.
| Country | Japan |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Koji Tamada |
Contact Details
Address: T&G Hamamatsucho Building Minato, 105-0012 Japan | |
| Website | noile-immune.com |
Stock Details
| Ticker Symbol | 4893 |
| Exchange | Tokyo Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| ISIN Number | JP3759560000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Koji Tamada | Chief Executive Officer |
| Hiroko Nagai | Chief Financial Officer |
| Tsutomu Tokashiki | Chief Operating Officer |